Major players seek fresh Radiopharmaceutical Therapy capabilities to craft distinctive oncology platforms. Fusion is competitively positioned based on its proprietary target alpha therapy platform, ...
Dr. Michel Laberge , Founder & Chief Science Officer, General Fusion Mike Donaldson , Senior Vice President, Technology Development, General Fusion Time: 11:00 a.m. - 3:00 p.m. ET In-person RSVP: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results